Abstract 471P
Background
Despite being a rare disease entity, Thymoma and Thymic carcinomas represent the most common cause of anterior mediastinal mass. Clinical course is widely varied from an indolent course to florid metastatic disease with paraneoplastic manifestation. Treatment guidelines are based on small phase 2 studies. Data of chemotherapy in advanced thymoma is limited.
Methods
It is a retrospective study of advanced thymic epithelial tumors treated with chemotherapy over a period of 7 years (2011 -2017). All patients with unresectable /metastatic thymic tumours and who have received chemotherapy as were included in the study. Independent review of radiology images and histopathology slides were performed.
Results
There were 55 cases registered with thymic malignancy and 32 cases were analyzed for present study. Among them 27 cases were thymoma, 3 were thymic carcinoma and 2 were thymic NET. The median age was 39 years (22 65 years). Male: female ratio was 3: 1. The median duration of symptoms was 5.9 months (0-36 months). Twelve cases (38%) had features of superior vena cava obstruction at presentation. The mean size of mediastinal mass was 8.9 + 3.26 (range 2-15 cm). More than half of the cases (56%) showed calcification. Mediastinal lymph nodes were seen in 14 patients (46%). There was pleural involvement in 14 patients (73%) and pericardial involvement in 13 cases (43%). Pleural effusion was seen in 17(53%). Only 5 cases had stage III, 18 had stage Iva and 9 had stage IVb disease. The most common histological subtype as per WHO classification was B1 in 11 patients (34%) followed by B3 in 9 patients (28%) in our cohort. Out of 32 cases 3 have had upfront R2 resection. Post chemotherapy, one case attained CR, 10 had PR, 13 had SD and 3 had PD. 6 cases underwent surgery post induction therapy. 3 had R1 resection and 3 had R2 resection. Cisplatin, doxorubicin and cyclophosphamide (CAP) remains first choice for chemotherapy in 81% patients followed by paclitaxel-carboplatin in 12.5%. Radiation therapy was given to 13 patients. After a median follow up of 24.86 months, median PFS is 16.1 months and median OS was not reached.
Conclusions
Thymic malignancies are a heterogeneous group of disorders. Multi-modality treatment including chemotherapy is an effective and feasible treatment for advanced thymoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
All authors are equally responsible. Institute ethics committee has given the clearance.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract